Skip to main content

Table 1 Baseline data of study participants

From: Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes

Item

Combination group (n=44)

Statins group (n=40)

P

Male/female

24/20

24/16

0.614

UA/NSTEMI/STEMI

21/14/9

24/10/6

0.528

ROS/ATOR/SIM/PRA

25/15/2/2

29/8/2/1

0.962

Age (year)

62 ± 1.5

64± 1.5

0.514

BMI

25.1± 0.15

24.7± 0.19

0.136

smoking/non-smoking

18/26

16/24

0.932

TC (mmol/L)

4.70± 0.17

4.43± 0.15

0.252

TG (mmol/L)

1.93± 0.17

2.02± 0.19

0.459

HDL-C (mmol/L)

1.00± 0.03

1.00± 0.04

0.966

LDL-C (mmol/L)

3.07± 0.14

2.70± 0.13

0.053

hs-CRP (mg/L)

4.55± 0.70

4.15±0.80

0.711

ALT (IU/L)

28± 3.5

30± 2.9

0.726

AST (IU/L)

61± 16

52±11

0.658

TBIL (Umol/L)

10.2± 0.68

9.7±0.66

0.724

Cr (μmol/L)

77.5± 4.52

78.6±5.59

0.871

FBG (mmol/L)

7.66± 0.39

8.27±0.62

0.092

HbA1C (%)

7.4±0.32

7.9±0.28

0.187

CK (U/L)

101±29

117±24

0.433

CK-MB (U/L)

23±7

19±6

0.547

TnI (μg/L)

16.17±4.85

12.14±4.52

0.545

  1. Data are presented as mean ±SE. P value less than 0.05 for significant difference between two groups at baseline.